Radiologic Features of Invasive Pulmonary Aspergillosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sung-Han Kim, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT01178177
First received: August 9, 2010
Last updated: May 14, 2013
Last verified: May 2013
  Purpose

Invasive pulmonary aspergillosis (IPA) is an opportunistic infection that primarily affects recipients of solid organ transplants (SOTs) and patients with chemotherapy- induced neutropenia.Although both of these populations are at high risk for IPA, they differ with regards to the specific defects in host defense mechanisms that increase their risk for IPA. Chemotherapy- induced neutropenia is the principal defect affecting patients with hematologic malignancies, whereas transplant recipients tend to have dysfunctional T cells and phagocytes, as a result of immunosuppressive drug therapy. Thus, the patterns of IPA-related infection and inflammation may differ according to the type of underlying immune defect. Although the clinical and radiological features of IPA in patients with neutropenia have been extensively studied, little is known about the characteristics of IPA in SOT recipients. The investigators therefore compared the IPA- related clinical and radiological findings in SOT recipients with those of neutropenic patients.


Condition
Hematologic Disease
Solid Organ Transplantation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Analysis of Radiologic Features of Invasive Pulmonary Aspergillosis in Transplant Recipients and Neutropenic Patients.Transplant Recipients and Neutropenic Patients

Resource links provided by NLM:


Further study details as provided by Asan Medical Center:

Enrollment: 130
Study Start Date: January 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
SOT recipients
solid organ transplant recipients with invasive pulmonary aspergillosis
Hematologic disease
Hematologic disease patients with invasive pulmonary aspergillosis

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All adult patients who are diagnosed with invasive pulmonary aspergillosis (IPA)between January 2008 and February 2010.

Criteria

Inclusion Criteria:

  • IPA cases with solid organ transplant recipients and hematologic disease patients
  • proven and probable invasive pulmonary aspergillosis by modified EORTC/MSG criteria

Exclusion Criteria:

  • under 16 years old
  • possible cases of invasive pulmonary aspergillosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178177

Sponsors and Collaborators
Asan Medical Center
Investigators
Study Chair: Sung-Han Kim, MD Department of Infectious Diseases, Asan Medical Center
  More Information

Publications:
Responsible Party: Sung-Han Kim, Assistantant Professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT01178177     History of Changes
Other Study ID Numbers: IPA -HEM vs SOT-2010
Study First Received: August 9, 2010
Last Updated: May 14, 2013
Health Authority: Korea: Institutional Review Board

Keywords provided by Asan Medical Center:
Invasive pulmonary aspergillosis
Solid organ transplantation
Hematologic disease

Additional relevant MeSH terms:
Aspergillosis
Hematologic Diseases
Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Hyalohyphomycosis
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Skin Diseases
Lung Diseases, Fungal
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 18, 2014